237 related articles for article (PubMed ID: 32239429)
1. Small molecule tyrosine kinase inhibitors in glioblastoma.
Kim G; Ko YT
Arch Pharm Res; 2020 Apr; 43(4):385-394. PubMed ID: 32239429
[TBL] [Abstract][Full Text] [Related]
2. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment.
Frumento D; Grossi G; Falesiedi M; Musumeci F; Carbone A; Schenone S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338677
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma.
Liu Z; Li H; He L; Xiang Y; Tian C; Li C; Tan P; Jing J; Tian Y; Du L; Huang Y; Han L; Li M; Zhou Y
Cell Chem Biol; 2019 Mar; 26(3):352-365.e7. PubMed ID: 30639261
[TBL] [Abstract][Full Text] [Related]
4. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
Mitra R; Ayyannan SR
ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
6. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
7. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
8. Battling Glioblastoma: A Novel Tyrosine Kinase Inhibitor with Multi-Dimensional Anti-Tumor Effect (Running Title: Cancer Cells Death Signalling Activation).
Viswanathan A; Musa A; Murugesan A; Vale JR; Afonso CAM; Konda Mani S; Yli-Harja O; Candeias NR; Kandhavelu M
Cells; 2019 Dec; 8(12):. PubMed ID: 31842391
[TBL] [Abstract][Full Text] [Related]
9. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
10. Current Development of Glioblastoma Therapeutic Agents.
Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.
Xu D; Zhou D; Bum-Erdene K; Bailey BJ; Sishtla K; Liu S; Wan J; Aryal UK; Lee JA; Wells CD; Fishel ML; Corson TW; Pollok KE; Meroueh SO
ACS Chem Biol; 2020 Jun; 15(6):1424-1444. PubMed ID: 32243127
[TBL] [Abstract][Full Text] [Related]
12. ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.
Aljohani H; Koncar RF; Zarzour A; Park BS; Lee SH; Bahassi el M
Oncotarget; 2015 Aug; 6(24):20388-95. PubMed ID: 25978031
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.
Cruickshanks N; Zhang Y; Hine S; Gibert M; Yuan F; Oxford M; Grello C; Pahuski M; Dube C; Guessous F; Wang B; Deveau C; Saoud K; Gallagher I; Wulfkuhle J; Schiff D; Phan S; Petricoin E; Abounader R
Clin Cancer Res; 2019 Jan; 25(2):663-673. PubMed ID: 30201763
[TBL] [Abstract][Full Text] [Related]
14. Small Molecules Targeting Activated Cdc42-Associated Kinase 1 (ACK1/TNK2) for the Treatment of Cancers.
Wang A; Pei J; Shuai W; Lin C; Feng L; Wang Y; Lin F; Ouyang L; Wang G
J Med Chem; 2021 Nov; 64(22):16328-16348. PubMed ID: 34735773
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?
Lucas MC; Tan SL
Future Med Chem; 2014; 6(16):1811-27. PubMed ID: 25407369
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.
Wang L; Zhao H; Cui K; Yao L; Ren M; Hao A; Smollen P; Nie F; Jin G; Liu Q; Wong ST
Biosci Trends; 2012 Aug; 6(4):192-200. PubMed ID: 23006966
[TBL] [Abstract][Full Text] [Related]
17. Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.
Lawrence HR; Mahajan K; Luo Y; Zhang D; Tindall N; Huseyin M; Gevariya H; Kazi S; Ozcan S; Mahajan NP; Lawrence NJ
J Med Chem; 2015 Mar; 58(6):2746-63. PubMed ID: 25699576
[TBL] [Abstract][Full Text] [Related]
18. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.
Nehoff H; Parayath NN; McConnell MJ; Taurin S; Greish K
Oncotarget; 2015 Nov; 6(35):37948-64. PubMed ID: 26517812
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic potential of Aurora kinases targeting in glioblastoma: from preclinical research to translational oncology.
de Almeida Magalhães T; de Sousa GR; Alencastro Veiga Cruzeiro G; Tone LG; Valera ET; Borges KS
J Mol Med (Berl); 2020 Apr; 98(4):495-512. PubMed ID: 32219470
[TBL] [Abstract][Full Text] [Related]
20. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
